INTRODUCTION

Obesity is defined as abnormal accumulation of excess fat following the intake of energy nutrients, which exceeds the amount of used energy. The prevalence of obesity is continuously increasing, leading to a global pandemic and this prevalence has also been accelerating in Asia.¹⁾ Obesity is an independent risk factor for the development and progression of cardiovascular disease (CVD) including myocardial infarction, heart failure, stroke, thromboembolic disease, and peripheral arterial disease.²⁾ Obesity is related to conventional risk factors of CVD such as hypertension, hyperlipidemia, and diabetes. Moreover, it increases insulin resistance and induces pro-coagulation, hypofibrinolysis, and oxidative stress through the action of inflammatory cytokines including adipokines that cause endothelial dysfunction and contribute to CVD.³⁾

Various cardiovascular outcomes are related to the association between body weight change and CVD. Metabolically healthy obese (MHO) individuals exhibit different body fat distribution and cardiovascular outcomes when compared with metabolically unhealthy obese (MUO) individuals.⁴⁾ In addition, weight gain and consequent metabolic changes after smoking cessation (SC) are different from those associated with simple obesity.⁵⁾ Unintentional loss of weight that is not due to lifestyle modifications is common among older adults and could be associated with poor cardiovascular outcomes.⁶⁾ Failure to maintain a healthy weight and fluctuations in weight (commonly referred to as weight cycling) put a strain on the cardiometabolic system.⁷⁾ Therefore, we aimed to review the pathophysiological mechanisms and clinical significance of weight change and its relationship with cardiovascular outcomes.

WEIGHT GAIN

Metabolically healthy vs. unhealthy obesity

Fat accumulation is heterogeneous. Subcutaneous and visceral adipose tissues differ in terms of blood flow and innervation, cell composition, and metabolic and endocrine functions.⁸⁾ Unlike peripheral subcutaneous fat, visceral fat is mainly associated with the exacerbation of metabolic profiles.⁹⁾¹⁰⁾ Regardless of the body mass index (BMI) or absolute fat volumes, a high visceral/subcutaneous adipose tissue ratio significantly worsens cardiometabolic risk and increases the possibility of subsequent CVD events.¹¹⁾¹²⁾ Moreover, fatty liver is associated with coronary artery calcification independent of the BMI and visceral fat.¹³⁾ Thus, the risk of metabolic diseases and CVD could differ according to the phenotype of obesity, even with similar amount of weight gain. Although there is no established definition, absence of insulin resistance and metabolic disease in obese individuals is referred to as the MHO phenotype.⁴⁾ In a prospective epidemiological study involving adult Caucasians, MHO individuals exhibited better fitness and better prognosis in terms of CVD mortality and morbidity than MUO individuals.¹⁴⁾ In a meta-analysis by Kramer et al.,¹⁵⁾ the risk of CVD was relatively lower in MHO subjects than in MUO subjects, but the risk significantly increased when compared with metabolically healthy normal-weight individuals even in the absence of metabolic abnormalities. The conversion from MHO to MUO phenotype over time has been commonly identified and is associated with an increase in the CVD risk in several studies.¹⁶⁾¹⁷⁾ Therefore, MHO phenotype should not be considered a harmless condition. Further research should define MHO and evaluate its effects on CVD.

Weight gain after SC

Smoking is a modifiable risk factor for CVD and there is strong evidence suggesting the immediate benefits of SC.¹⁸⁾ However, SC causes significant weight gain. In a meta-analysis combining 62 studies, a weight gain of approximately 4–5 kg was observed after 1 year of SC.¹⁹⁾ Nicotine deficiency and subsequent changes in appetite and energy metabolism induced by SC lead to weight gain.⁵⁾ Studies have demonstrated an increase in visceral fat and deterioration of metabolic profile characterized by elevated blood pressure and cholesterol, elevated fasting blood glucose, and insulin resistance after SC.^20-22) Nevertheless, recent studies have demonstrated that weight gain and consequent worsening of metabolic profile after SC do not impair the protective benefit of SC regarding the development and prognosis of CVD.^23-26)

The fear of weight gain could be associated with failure to start SC, not receiving treatment, and even relapse after SC.²⁷⁾²⁸⁾ Some researchers have suggested that vigorous exercise combined with cognitive-behavioral therapy or medications could resolve this condition.²⁹⁾³⁰⁾ However, there is a lack of sufficient evidence to recommend specific clinical methods for preventing weight gain after SC.³¹⁾ Therefore, SC should be encouraged to lower the risk of CVD and future studies should focus on finding an appropriate intervention for weight gain and subsequent metabolic and cosmetic problems caused by SC.

WEIGHT LOSS

Intentional vs. unintentional weight loss (IWL vs. UWL)

Achieving weight loss through lifestyle modifications, bariatric surgery, or the use of drugs such as glucagon-like peptide-1 agonists in obese individuals can improve cardiometabolic conditions.^32-34) IWL not only improves the metabolic profile but also improves the structure and function of the left ventricle directly or indirectly, contributing to the prevention of CVD.²⁾ The importance of intensive lifestyle intervention through caloric restriction and exercise was strongly recognized in the Diabetes Prevention Program trial.³⁵⁾ Studies regarding the effectiveness of IWL in preventing CVD have demonstrated consistent cardiovascular benefits.³⁶⁾³⁷⁾ However, some studies wherein the intention of weight loss was not identified have suggested that weight loss could be a warning sign of cardiovascular events.³⁸⁾³⁹⁾ UWL caused by organic diseases such as malignancies, psychocognitive disorders, or unknown causes could be associated with morbidity and mortality.⁶⁾ The pathophysiology of UWL is currently unknown, but it could be assumed that weight maintenance is impaired by alterations in the balance of energy intake, absorption, utilization, and loss.⁴⁰⁾ Compared to IWL, UWL was associated with older age, poorer health status, smoking, and lower BMI.⁴¹⁾ Even after adjusting for these confounding factors, UWL was independently and significantly associated with the incidence of CVD and associated mortality.⁴²⁾⁴³⁾ However, a meta-analysis involving 178,644 participants revealed that UWL did not show a protective effect against major adverse cardiovascular events even in overweight or obese participants.⁴⁴⁾

Obesity paradox and sarcopenia

The concept of “obesity paradox” and CVD outcome, first introduced by Gruberg et al.,⁴⁵⁾ could be explained by the negative effect of UWL on the risk of CVD. The outcome of various CVDs including chronic heart failure showed a better “U-shaped” or “J-shaped” relationship in overweight to mildly obese individuals when compared with lean ones.⁴⁶⁾ In addition to the differences in regional fat distribution,⁸⁾ the differences in molecular phenotyping of adipose tissue in this “low-risk” obesity, which is metabolically benign and protects against the risk of CVD, are in terms of following factors: secretomic profile, cell turnover and expansion, extracellular matrix fibrosis, angiogenesis, inflammation, and adipocyte browning.⁴⁷⁾ In addition, fitness is more important than “fatness” and it notably alters the relationship between obesity and CVD outcomes.⁴⁸⁾ Substantial evidence suggests that fitness is a critical component of obesity paradox and it significantly affects the major cardiovascular outcomes.^14)49)50)

Sarcopenia is defined as involuntary weight loss with key characteristics of loss of muscle mass and weakening of muscle strength, resulting in poor physical performance.⁵¹⁾ In a study involving elderly Korean individuals aged over 65 years, sarcopenia was confirmed via the loss of skeletal muscle mass on dual-energy X-ray absorptiometry in approximately 30% of the subjects and it was associated with the presence of CVD.⁵²⁾ Frailty (UWL with low levels of physical activity or illness) in the elderly individuals independently increases the risk of CVD and worsens the prognosis.⁵³⁾⁵⁴⁾ The common factor between the obesity paradox and sarcopenia is a phenomenon that can be interpreted as a progressive catabolic state, loss of lean mass, and subsequent lack of fitness. With a progress in future research to clearly understand the pathophysiology of UWL, we should identify the intentionality and manage the causes of weight loss, bearing in mind that the risk of CVD could increase in people with loss of muscle mass and fitness, especially in elderly individuals.

Weight cycling

It is necessary to maintain a healthy weight in overweight or obese individuals who have achieved a healthy weight goal through intensive lifestyle intervention. However, weight regain is an important issue for those who were successful in losing weight. Weight cycling, the concept of failure to maintain a healthy weight, has a negative influence on the cardiometabolic system through increased cardiac load, glomerular damage, vascular injuries, and worsening insulin resistance (Figure 1).⁷⁾ Weight cycling was related to increasing T-cell accumulation in the adipose tissue and impaired systemic glucose tolerance in an in vivo study.⁵⁵⁾ In the Look AHEAD study to understand the effect of weight regain, partial or full weight recovery was identified in the majority of the overweight and obese participants who achieved IWL of ≥3% of their initial weight.⁵⁶⁾ Furthermore, in a subsequent study by Berger et al.,⁵⁷⁾ cardiometabolic parameters that improved with weight loss deteriorated with weight regain among the participants of the Look AHEAD trial. Similar association with the deterioration of metabolic profile was consistently observed in other studies.⁵⁸⁾⁵⁹⁾ The phenomenon of accelerated fat recovery after weight loss (catch-up fat) could explain the associations with abdominal obesity and metabolic diseases.⁶⁰⁾ The beneficial effects of cardiac structure and function achieved by weight loss are partially lost after weight is regained.⁶¹⁾ Studies that confirmed the association of weight cycling with CVD outcomes mainly demonstrated its independent association with unfavorable CVD prevalence and prognosis.^62-64) However, some researchers have argued that there was sparse evidence regarding the adverse effects of weight cycling on cardiometabolic risk and mortality.⁶⁵⁾⁶⁶⁾

CONCLUSION

Advancing from the past concept that emphasized only the increasing CVD risk of simple obesity and the protective effect of weight loss, a wide variety of CVD outcomes could be derived according to weight cycling as well as according to the various phenotypes of weight gain and weight loss. We suggest that it is important to evaluate not only the CVD risk with simple weight gain or BMI gain but also the causes of weight change and complementary health factors such as lean body mass and fitness. The definition of each phenotype of weight change and its categories have not been established definitively. Moreover, the pathophysiological aspects that cannot be explained by the current hypothesis remain a topic of further research. Therefore, future studies should focus on evaluating the impact of weight change on CVD by identifying unknown pathophysiology and formulating appropriate management and intervention strategies for the various phenotypes of weight change.

ARTICLE INFORMATION

Conflict of Interest

The authors have no financial conflicts of interest.

Author Contributions

Supervision: Lee WY; Writing - original draft: Cho JH; Writing - review & editing: Rhee EJ, Lee WY.

Figure 1.

Mechanisms of weight cycling effects on cardiometabolic health outcomes.⁷⁾

GFR = glomerular filtration rate.

REFERENCES

• 1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017;390:2627–42.PubMedPMC
• 2. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898–918.ArticlePubMed
• 3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875–80.ArticlePubMed
• 4. Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 2013;1:152–62.ArticlePubMed
• 5. Harris KK, Zopey M, Friedman TC. Metabolic effects of smoking cessation. Nat Rev Endocrinol 2016;12:299–308.ArticlePubMedPMC
• 6. McMinn J, Steel C, Bowman A. Investigation and management of unintentional weight loss in older adults. BMJ 2011;342:d1732. ArticlePubMed
• 7. Lee SH, Kim MK, Rhee EJ. Effects of cardiovascular risk factor variability on health outcomes. Endocrinol Metab 2020;35:217–26.Article
• 8. Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, Kirkland JL. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 2013;17:644–56.ArticlePubMedPMC
• 9. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697–738.ArticlePubMed
• 10. Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT. Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: The Framingham Heart Study. Am J Med 2018;131:684. –692. e12ArticlePubMedPMC
• 11. Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia 2012;55:2622–30.ArticlePubMedPMC
• 12. Figueroa AL, Takx RA, MacNabb MH, Abdelbaky A, Lavender ZR, Kaplan RS, Truong QA, Lo J, Ghoshhajra BB, Grinspoon SK, Hoffmann U, Tawakol A. Relationship between measures of adiposity, arterial inflammation, and subsequent cardiovascular events. Circ Cardiovasc Imaging 2016;9:e004043.ArticlePubMedPMC
• 13. Liu J, Musani SK, Bidulescu A, Carr JJ, Wilson JG, Taylor HA, Fox CS. Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study. Atherosclerosis 2012;224:521–5.ArticlePubMedPMC
• 14. Ortega FB, Lee DC, Katzmarzyk PT, Ruiz JR, Sui X, Church TS, Blair SN. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J 2013;34:389–97.ArticlePubMed
• 15. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med 2013;159:758–69.ArticlePubMed
• 16. Mongraw-Chaffin M, Foster MC, Anderson CA, Burke GL, Haq N, Kalyani RR, Ouyang P, Sibley CT, Tracy R, Woodward M, Vaidya D. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2018;71:1857–65.ArticlePubMedPMC
• 17. Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol 2018;6:714–24.ArticlePubMed
• 18. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:3243–7.ArticlePubMed
• 19. Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: metaanalysis. BMJ 2012;345:e4439.ArticlePubMedPMC
• 20. Matsushita Y, Nakagawa T, Yamamoto S, Takahashi Y, Noda M, Mizoue T. Associations of smoking cessation with visceral fat area and prevalence of metabolic syndrome in men: the Hitachi health study. Obesity (Silver Spring) 2011;19:647–51.ArticlePubMed
• 21. Kim BJ, Kim BS, Sung KC, Kang JH, Lee MH, Park JR. Association of smoking status, weight change, and incident metabolic syndrome in men: a 3-year follow-up study. Diabetes Care 2009;32:1314–6.ArticlePubMedPMC
• 22. Stadler M, Tomann L, Storka A, Wolzt M, Peric S, Bieglmayer C, Pacini G, Dickson SL, Brath H, Bech P, Prager R, Korbonits M. Effects of smoking cessation on β-cell function, insulin sensitivity, body weight, and appetite. Eur J Endocrinol 2014;170:219–7.ArticlePubMed
• 23. Clair C, Rigotti NA, Porneala B, Fox CS, D'Agostino RB, Pencina MJ, Meigs JB. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013;309:1014–21.ArticlePubMedPMC
• 24. Kim K, Park SM, Lee K. Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men. Eur Heart J 2018;39:1523–31.ArticlePubMedPMC
• 25. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med 2018;379:623–32.ArticlePubMedPMC
• 26. Cho JH, Kwon HM, Park SE, Jung JH, Han KD, Park YG, Kim YH, Rhee EJ, Lee WY. Protective effect of smoking cessation on subsequent myocardial infarction and ischemic stroke independent of weight gain: a nationwide cohort study. PLoS One 2020;15:e0235276.ArticlePubMedPMC
• 27. Meyers AW, Klesges RC, Winders SE, Ward KD, Peterson BA, Eck LH. Are weight concerns predictive of smoking cessation? A prospective analysis. J Consult Clin Psychol 1997;65:448–52.ArticlePubMed
• 28. Pomerleau CS, Zucker AN, Stewart AJ. Characterizing concerns about post-cessation weight gain: results from a national survey of women smokers. Nicotine Tob Res 2001;3:51–60.ArticlePubMed
• 29. Marcus BH, Albrecht AE, King TK, Parisi AF, Pinto BM, Roberts M, Niaura RS, Abrams DB. The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. Arch Intern Med 1999;159:1229–34.ArticlePubMed
• 30. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H, Matthews AK, Stachoviak RJ. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol 2012;32:630–6.ArticlePubMedPMC
• 31. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012;1:CD006219. ArticlePubMed
• 32. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–37.ArticlePubMed
• 33. Yamaoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med 2012;10:138. ArticlePubMedPMC
• 34. Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002.ArticlePubMed
• 35. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165–71.PubMed
• 36. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev 2016;17:1001–11.ArticlePubMed
• 37. Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, Zhang B, Feng X, Li H, Chen X, Cheng YJ, Gregg EW, Hu Y, Bennett PH, Li G; Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol 2019;7:452–61.ArticlePubMedPMC
• 38. Galanis DJ, Harris T, Sharp DS, Petrovitch H. Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol 1998;147:379–86.ArticlePubMed
• 39. Stevens J, Erber E, Truesdale KP, Wang CH, Cai J. Long- and short-term weight change and incident coronary heart disease and ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2013;178:239–48.ArticlePubMedPMC
• 40. Bouras EP, Lange SM, Scolapio JS. Rational approach to patients with unintentional weight loss. Mayo Clin Proc 2001;76:923–9.ArticlePubMed
• 41. Meltzer AA, Everhart JE. Unintentional weight loss in the United States. Am J Epidemiol 1995;142:1039–46.ArticlePubMed
• 42. Wannamethee SG, Shaper AG, Lennon L. Reasons for intentional weight loss, unintentional weight loss, and mortality in older men. Arch Intern Med 2005;165:1035–40.ArticlePubMed
• 43. Lee AK, Woodward M, Wang D, Ohkuma T, Warren B, Sharrett AR, Williams B, Marre M, Hamet P, Harrap S, Mcevoy JW, Chalmers J, Selvin E. The risks of cardiovascular disease and mortality following weight change in adults with diabetes: results from ADVANCE. J Clin Endocrinol Metab 2020;105:152–62.ArticlePubMed
• 44. De Stefani FD, Pietraroia PS, Fernandes-Silva MM, Faria-Neto J, Baena CP. Observational evidence for unintentional weight loss in all-cause mortality and major cardiovascular events: a systematic review and meta-analysis. Sci Rep 2018;8:15447. ArticlePubMedPMC
• 45. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed LM, Kent KM, Pichard AD, Suddath WO, Satler LF, Lindsay J Jr. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578–84.ArticlePubMed
• 46. Hainer V, Aldhoon-Hainerová I. Obesity paradox does exist. Diabetes Care 2013;36 Suppl 2:S276–81.ArticlePubMed
• 47. Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res 2017;113:1074–86.ArticlePubMed
• 48. Lavie CJ, De Schutter A, Milani RV. Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol 2015;11:55–62.ArticlePubMed
• 49. McAuley PA, Beavers KM. Contribution of cardiorespiratory fitness to the obesity paradox. Prog Cardiovasc Dis 2014;56:434–40.ArticlePubMed
• 50. Moholdt T, Lavie CJ, Nauman J. Sustained physical activity, not weight loss, associated with improved survival in coronary heart disease. J Am Coll Cardiol 2018;71:1094–101.ArticlePubMed
• 51. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31.ArticlePubMed
• 52. Chin SO, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, Ahn KJ, Chung HY, Woo JT, Kim SW, Kim JW, Kim YS, Ahn HY. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS One 2013;8:e60119.ArticlePubMedPMC
• 53. Matsuzawa Y, Konishi M, Akiyama E, Suzuki H, Nakayama N, Kiyokuni M, Sumita S, Ebina T, Kosuge M, Hibi K, Tsukahara K, Iwahashi N, Endo M, Maejima N, Saka K, Hashiba K, Okada K, Taguri M, Morita S, Sugiyama S, Ogawa H, Sashika H, Umemura S, Kimura K. Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2013;61:1964–72.ArticlePubMed
• 54. Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S, Corti MC, Baggio G, Toffanello ED, Crepaldi G, Perissinotto E, Manzato E. Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study. J Am Coll Cardiol 2015;65:976–83.PubMed
• 55. Anderson EK, Gutierrez DA, Kennedy A, Hasty AH. Weight cycling increases T-cell accumulation in adipose tissue and impairs systemic glucose tolerance. Diabetes 2013;62:3180–8.ArticlePubMedPMC
• 56. Wing RR, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, Unick J, Wadden T, Wagenknecht L; Action for Health in Diabetes (Look AHEAD) Study Group. Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care 2016;39:1345–55.ArticlePubMedPMC
• 57. Berger SE, Huggins GS, McCaffery JM, Jacques PF, Lichtenstein AH. Change in cardiometabolic risk factors associated with magnitude of weight regain 3 years after a 1-year intensive lifestyle intervention in type 2 diabetes mellitus: The Look AHEAD Trial. J Am Heart Assoc 2019;8:e010951.ArticlePubMedPMC
• 58. Olson MB, Kelsey SF, Bittner V, Reis SE, Reichek N, Handberg EM, Merz CN. Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report from the NHLBIsponsored WISE study. J Am Coll Cardiol 2000;36:1565–71.PubMed
• 59. Vergnaud AC, Bertrais S, Oppert JM, Maillard-Teyssier L, Galan P, Hercberg S, Czernichow S. Weight fluctuations and risk for metabolic syndrome in an adult cohort. Int J Obes 2008;32:315–21.Article
• 60. Dulloo AG, Jacquet J, Montani JP. Pathways from weight fluctuations to metabolic diseases: focus on maladaptive thermogenesis during catch-up fat. Int J Obes Relat Metab Disord 2002;26 Suppl 2:S46–57.ArticlePubMed
• 61. de las Fuentes L, Waggoner AD, Mohammed BS, Stein RI, Miller BV 3rd, Foster GD, Wyatt HR, Klein S, Davila-Roman VG. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J Am Coll Cardiol 2009;54:2376–81.ArticlePubMedPMC
• 62. Lissner L, Odell PM, D'Agostino RB, Stokes J 3rd, Kreger BE, Belanger AJ, Brownell KD. Variability of body weight and health outcomes in the Framingham population. N Engl J Med 1991;324:1839–44.ArticlePubMed
• 63. French SA, Folsom AR, Jeffery RW, Zheng W, Mink PJ, Baxter JE. Weight variability and incident disease in older women: the Iowa Women's Health Study. Int J Obes Relat Metab Disord 1997;21:217–23.ArticlePubMed
• 64. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 2017;376:1332–40.ArticlePubMed
• 65. Lee JS, Kawakubo K, Kobayashi Y, Mori K, Kasihara H, Tamura M. Effects of ten year body weight variability on cardiovascular risk factors in Japanese middle-aged men and women. Int J Obes Relat Metab Disord 2001;25:1063–7.ArticlePubMed
• 66. Mehta T, Smith DL Jr, Muhammad J, Casazza K. Impact of weight cycling on risk of morbidity and mortality. Obes Rev 2014;15:870–81.ArticlePubMedPMC

Figure & Data

References

Citations

Citations to this article as recorded by  

• Investigating the efficacy and feasibility of using a whole-of-diet approach to lower circulating levels of C-reactive protein in postmenopausal women: a mixed methods pilot study
  Stephanie Cowan, Aimee Dordevic, Andrew J. Sinclair, Helen Truby, Surbhi Sood, Simone Gibson
  Menopause.2023; 30(7): 738.     CrossRef